Compare · DFTX vs UPXI
DFTX vs UPXI
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Upexi Inc. (UPXI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and UPXI operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $6.02B, about 75.2x UPXI ($80.1M).
- Over the past year, DFTX is up 344.3% and UPXI is down 87.8% - DFTX leads by 432.1 points.
- DFTX has hit the wire 16 times in the past 4 weeks while UPXI has been quiet.
- DFTX has more recent analyst coverage (7 ratings vs 2 for UPXI).
PerformanceDFTX+344.33%UPXI-87.78%
2025-08-26+0.00%2026-08-26
- Company
- Definium Therapeutics Inc.
- Upexi Inc.
- Price
- $44.30-1.04%
- $1.04-3.69%
- Market cap
- $6.02B
- $80.1M
- 1M return
- +5.58%
- +17.44%
- 1Y return
- +344.33%
- -87.78%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 16
- 0
- Recent ratings
- 7
- 2
Latest DFTX
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Latest UPXI
- Upexi Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Director Salkind Gene was granted 100,000 shares, increasing direct ownership by 46% to 318,750 units (SEC Form 4)
- Director Dugan Lawrence was granted 100,000 shares, increasing direct ownership by 86% to 216,389 units (SEC Form 4)
- Chief Strategy Officer Rudick Brian Benjamin was granted 400,000 shares, increasing direct ownership by 48% to 1,238,597 units (SEC Form 4)
- Chief Executive Officer Marshall Allan was granted 2,000,000 shares, increasing direct ownership by 49% to 6,046,261 units (SEC Form 4)
- Chief Financial Officer Norstrud Andrew James was granted 400,000 shares, increasing direct ownership by 62% to 1,049,138 units (SEC Form 4)
- SEC Form EFFECT filed by Upexi Inc.
- SEC Form 424B3 filed by Upexi Inc.
- SEC Form S-3 filed by Upexi Inc.
- Upexi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits